James Lewis Abbruzzese

James Lewis Abbruzzese's AcademicInfluence.com Rankings

Medical

#379

World Rank

#533

Historical Rank

Oncology

#14

World Rank

#15

Historical Rank

Gastroenterology

#17

World Rank

#17

Historical Rank

medical Degrees

Download Badge

Medical

James Lewis Abbruzzese's Degrees

Doctorate Medicine University of Pennsylvania
PhD Molecular Biology University of Pennsylvania

Why Is James Lewis Abbruzzese Influential?

(Suggest an Edit or Addition)

According to Wikipedia, James Lewis Abbruzzese is the Chief of the Duke Division of Medical Oncology and associate director for Clinical Research for the Duke Cancer Institute. Previously, Abbruzzese was Chairman of the Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center where he held the M. G. and Lillie A. Johnson Chair for Cancer Treatment and Research and the Annie Laurie Howard Research Distinguished Professorship. Abbruzzese is one of the world's leaders in the clinical study and treatment of pancreatic cancer.

(See a Problem?)

James Lewis Abbruzzese's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. (2000) (2515)
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer (2008) (1144)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006) (843)
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. (2009) (785)
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy (2006) (762)
Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus (2002) (738)
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. (1991) (725)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (2008) (699)
Metastatic patterns in adenocarcinoma (2006) (684)
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. (2007) (634)
Antidiabetic therapies affect risk of pancreatic cancer. (2009) (599)
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. (2009) (597)
The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells (1999) (595)
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. (2010) (579)
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. (1997) (548)
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis (2003) (543)
Pancreatic cancer (2004) (541)
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. (2000) (527)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. (2004) (489)
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. (2003) (487)
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. (2003) (475)
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. (2010) (464)
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma (2009) (449)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (2008) (444)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators (2012) (444)
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (2000) (441)
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. (2008) (406)
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. (2009) (402)
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice (2009) (338)
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. (1994) (337)
Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration (2001) (336)
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. (2002) (335)
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. (2003) (334)
Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass Spectrometry (2004) (332)
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. (2009) (327)
NF-κB and AP-1 Connection: Mechanism of NF-κB-Dependent Regulation of AP-1 Activity (2004) (326)
Risk Factors for Pancreatic Cancer: Case-Control Study (2007) (317)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. (2006) (315)
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. (2001) (315)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma (2007) (312)
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. (1999) (310)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. (2005) (307)
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma (2010) (306)
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. (1995) (303)
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. (2005) (301)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis (2008) (294)
Phase I study of recombinant human endostatin in patients with advanced solid tumors. (2002) (292)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers (2008) (284)
Improved Overall Survival Among Responders to Preoperative Chemoradiation for Locally Advanced Rectal Cancer (2001) (280)
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer (2012) (280)
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy (2007) (270)
ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma (2011) (267)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells (2004) (265)
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial (2001) (264)
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. (2011) (263)
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. (1999) (261)
Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer (2017) (261)
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? (2013) (256)
Nuclear factor‐κB and IκB kinase are constitutively active in human pancreatic cells, and their down‐regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis (2004) (253)
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. (1999) (251)
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. (2006) (249)
Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity (2004) (244)
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. (1994) (243)
Diagnostic strategies for unknown primary cancer (2004) (242)
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. (1998) (235)
Cytokines in pancreatic carcinoma (2004) (234)
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. (2009) (231)
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. (2008) (229)
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. (1994) (227)
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. (2005) (225)
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells (2001) (222)
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. (2001) (214)
The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances (2003) (214)
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? (2001) (213)
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. (2011) (212)
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. (1990) (210)
Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine (2004) (210)
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (2006) (207)
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma (2012) (204)
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. (2009) (203)
Function of Nuclear Factor κB in Pancreatic Cancer Metastasis (2003) (202)
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. (2005) (200)
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. (2006) (199)
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. (2002) (193)
Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. (2002) (190)
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. (2010) (186)
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA (1999) (179)
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head* (1996) (175)
Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival (2013) (174)
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. (2006) (174)
Association between hepatitis B virus and pancreatic cancer. (2008) (174)
Opportunities for targeted therapies in hepatocellular carcinoma. (2005) (169)
A multispecialty approach to the diagnosis and management of pancreatic cancer (2000) (168)
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. (2004) (165)
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. (2003) (162)
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. (2005) (161)
Hepatic resection: the last surgical frontier for colorectal cancer. (2005) (157)
Transport properties of pancreatic cancer describe gemcitabine delivery and response. (2014) (156)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies (2010) (155)
The function of multiple IκB : NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis (2002) (152)
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. (1997) (152)
Docetaxel enhances tumor radioresponse in vivo. (1997) (150)
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. (2011) (149)
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. (1999) (149)
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer (2005) (148)
Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma (2012) (146)
Association between hypothyroidism and hepatocellular carcinoma: A case‐control study in the United States (2009) (144)
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer (2008) (140)
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. (2009) (140)
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. (2006) (139)
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study (2005) (138)
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. (2005) (138)
Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival (2006) (135)
Mechanisms of Proinflammatory Cytokine-Induced Biphasic NF-κB Activation. (2003) (135)
Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma (2011) (134)
Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation (2010) (132)
Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. (1999) (131)
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. (2005) (129)
Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis (2003) (129)
Major vascular resection as part of pancreaticoduodenectomy for cancer: Radiologic, intraoperative, and pathologic analysis (1999) (129)
Function of nuclear factor kappaB in pancreatic cancer metastasis. (2003) (127)
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. (1996) (127)
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells (2006) (126)
Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-κB* (2004) (126)
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. (2008) (124)
Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma (2011) (123)
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience (2016) (122)
Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. (2007) (121)
The Need for Standardized Pathologic Staging of Pancreaticoduodenectomy Specimens (1996) (120)
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. (2006) (118)
Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? (2007) (118)
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. (2002) (117)
Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts (2002) (115)
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. (2011) (114)
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine (2009) (114)
Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. (1999) (113)
Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma (2008) (113)
A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease (2012) (113)
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. (2006) (111)
Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. (2007) (111)
Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. (2000) (108)
Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression (2012) (108)
Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. (1998) (107)
NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells (2004) (107)
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. (2005) (105)
Lifestyle, Occupational, and Reproductive Factors in Relation to Pancreatic Cancer Risk (2007) (104)
Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity (2009) (101)
Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary (2011) (101)
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. (2011) (100)
Serum Cadmium Levels in Pancreatic Cancer Patients from the East Nile Delta Region of Egypt (2005) (99)
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma (1996) (99)
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow (2008) (98)
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. (2002) (98)
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. (2012) (98)
Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer (2011) (96)
Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. (2000) (96)
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? (1997) (96)
Solid Pseudopapillary Neoplasm of the Pancreas: Clinicopathologic and Survival Analyses of 64 Cases From A Single Institution (2014) (95)
Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells (2008) (95)
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination (2011) (94)
Thalidomide in the treatment of patients with hepatocellular carcinoma (2005) (93)
Near-Infrared Optical Imaging of Integrin αvβ3 in Human Tumor Xenografts (2004) (93)
Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors (2007) (93)
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. (1998) (93)
Expression of MAP4K4 Is Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma (2008) (93)
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. (1990) (92)
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. (2004) (91)
A phase I surrogate endpoint study of SU6668 in patients with solid tumors (2004) (89)
Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial (2012) (88)
Surrogate markers in antiangiogenesis clinical trials (2003) (87)
Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype (2011) (87)
Tumor Suppressor MMAC/PTEN Inhibits Cytokine-induced NFκB Activation without Interfering with the IκB Degradation Pathway* (2001) (87)
Unknown primary tumors metastatic to liver. (1998) (86)
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. (2000) (86)
K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer Patients: In Relation to Cigarette Smoking (2007) (86)
Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. (2006) (86)
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors (2006) (85)
DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. (2002) (84)
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. (2002) (84)
New applications of gemcitabine and future directions in the management of pancreatic cancer (2002) (83)
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (2010) (82)
Retracted: In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer (2007) (82)
Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine (2010) (82)
Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. (1995) (81)
Epidermal growth factor receptor-targeted therapy for pancreatic cancer. (2002) (80)
Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case‐control study (2008) (80)
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. (2006) (80)
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. (2009) (79)
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. (2007) (79)
DNA Repair Gene Polymorphisms and Risk of Pancreatic Cancer (2009) (79)
The biology of unknown primary tumors. (1993) (78)
Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells (2006) (77)
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (2000) (77)
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation (2006) (77)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells (2005) (77)
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors (2008) (77)
Body Mass Index and Obesity- and Diabetes-Associated Genotypes and Risk for Pancreatic Cancer (2011) (77)
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer (2005) (76)
XRCC2 and XRCC3 Gene Polymorphismand Risk of Pancreatic Cancer (2008) (75)
Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin (2005) (75)
Post‐therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation (2012) (75)
Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. (2003) (74)
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (2006) (74)
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. (2001) (74)
Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases (2007) (73)
DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. (1998) (73)
Neoplasms of the Exocrine Pancreas (2003) (72)
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. (1995) (72)
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer (2001) (72)
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction (2013) (71)
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. (2005) (71)
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. (2003) (71)
Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. (2002) (70)
Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors (2008) (69)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) (2009) (69)
Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development (2018) (68)
Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. (1989) (68)
Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. (2003) (67)
Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. (2004) (67)
5,10-Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Pancreatic Cancer (2005) (67)
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study (2006) (66)
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. (2002) (65)
Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma (2013) (65)
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer (2017) (65)
Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation (2012) (64)
The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma (2013) (64)
Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome (2011) (64)
Overexpression of synuclein‐γ in pancreatic adenocarcinoma (2004) (63)
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression (2009) (63)
New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts (2010) (63)
Cognitive functioning in cancer patients (1992) (63)
Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. (2001) (62)
Dietary Mutagen Exposure and Risk of Pancreatic Cancer (2007) (62)
Synergistic effects of multiple natural products in pancreatic cancer cells. (2008) (62)
Adenovirus-mediated wild-typep53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer (1998) (61)
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. (2004) (61)
The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) (2007) (61)
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. (2001) (61)
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. (2001) (61)
Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer (2008) (61)
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. (2000) (60)
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma (2015) (60)
Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. (2000) (60)
Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer (2002) (59)
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. (2001) (58)
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. (2005) (58)
Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer (2008) (58)
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. (1996) (58)
Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab (2005) (57)
Aurora-A and p16 Polymorphisms Contribute to an Earlier Age at Diagnosis of Pancreatic Cancer in Caucasians (2007) (57)
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. (1991) (57)
The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. (2007) (57)
Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. (2004) (56)
A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis (2003) (56)
Glutathione S‐transferase gene polymorphisms and risk and survival of pancreatic cancer (2007) (56)
Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation (2009) (55)
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers (2005) (55)
Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis (2013) (55)
Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts (2004) (54)
Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. (2006) (54)
Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414) (2012) (52)
Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines (2006) (52)
Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. (2007) (52)
Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. (2010) (51)
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. (2007) (51)
Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome (2013) (51)
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. (2005) (51)
AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. (2005) (50)
p53 gene mutation spectrum in human unknown primary tumors. (1993) (50)
NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. (2004) (50)
Effects of base excision repair gene polymorphisms on pancreatic cancer survival (2007) (50)
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck (2001) (50)
A Pilot Clinical Trial of the Cholecystokinin Receptor Antagonist MK‐329 in Patients with Advanced Pancreatic Cancer (1992) (49)
The convergence of cancer prevention and therapy in early-phase clinical drug development. (2004) (49)
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin (2001) (49)
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial (2022) (49)
Effect of Insulin-Like Growth Factor Gene Polymorphisms Alone or In Interaction with Diabetes on the Risk of Pancreatic Cancer (2008) (48)
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. (2009) (48)
Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer (2010) (48)
Prognostic factors in resectable pancreatic cancer: p53 and Bcl-2 (1999) (48)
Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer (2008) (48)
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer (2011) (48)
Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. (2006) (47)
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. (2016) (47)
Phase I studies with the novel nucleoside analog gemcitabine. (1996) (47)
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. (1998) (47)
Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. (2006) (47)
Phase II evaluation of fluorouracil and recombinant α‐2a‐interferon in previously untreated patients with pancreatic adenocarcinoma (1992) (46)
Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. (2001) (46)
Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death (2007) (45)
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. (1988) (45)
Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy (2012) (45)
V‐CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials (2011) (44)
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. (1998) (44)
From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. (2015) (43)
Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. (2009) (43)
Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic Chemotherapy (2002) (43)
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity (2009) (43)
NCCN practice guidelines for pancreatic cancer. (1997) (43)
BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation (2013) (43)
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. (1997) (42)
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. (1994) (42)
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. (2005) (41)
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. (1998) (40)
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors (2004) (40)
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer (2015) (40)
SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. (2014) (40)
Overexpression of synuclein-gamma in pancreatic adenocarcinoma. (2004) (39)
Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification (2013) (39)
Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. (2011) (39)
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. (2006) (38)
Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. (2007) (38)
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. (1992) (38)
High Levels of Nucleolar Expression of Nucleolin Are Associated with Better Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma (2010) (37)
Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. (2019) (37)
Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF. (2006) (37)
Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. (2012) (37)
The CUL7/F-box and WD Repeat Domain Containing 8 (CUL7/Fbxw8) Ubiquitin Ligase Promotes Degradation of Hematopoietic Progenitor Kinase 1* (2013) (37)
Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. (1990) (37)
The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. (2018) (36)
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. (2004) (36)
Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer (2011) (36)
Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study (2004) (35)
Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. (2006) (35)
Unknown primary tumors. (1992) (35)
Overexpression of Oncogenic STK 15 / BTAK / Aurora A Kinase in Human Pancreatic Cancer 1 (2003) (35)
The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. (2000) (34)
Geographical Clustering of Pancreatic Cancers in the Northeast Nile Delta Region of Egypt (2006) (34)
Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. (2001) (34)
Current Approaches and Future Strategies for Pancreatic Carcinoma (2000) (34)
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. (2006) (34)
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. (2005) (34)
Early effects of imatinib mesylate on the expression of insulin‐like growth factor binding protein‐3 and positron emission tomography in patients with gastrointestinal stromal tumor (2006) (34)
I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score (2011) (33)
Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells (1996) (33)
Development of a Novel c-MET–Based CTC Detection Platform (2016) (33)
Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer (2007) (33)
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. (1995) (33)
Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. (1997) (32)
Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. (1997) (32)
Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE (2013) (32)
Treatment of advanced colorectal cancer. (1989) (32)
The Subcellular Localization of Syntaxin 17 Varies Among Different Cell Types and Is Altered in Some Malignant Cells (2005) (31)
Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (1998) (31)
A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy (2001) (31)
Association of diabetes and perineural invasion in pancreatic cancer (2012) (31)
Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer (2011) (31)
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. (2016) (30)
Modified cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma (2013) (30)
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer (2014) (30)
Pancreatic intraepithelial neoplasia and histological changes in non‐neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (2013) (30)
Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cyclea (1999) (29)
Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)–DNA adducts in human pancreatic tissues (2006) (29)
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial (2011) (28)
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. (2002) (28)
Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. (2012) (28)
Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial (1998) (28)
Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. (2006) (28)
Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. (2009) (28)
Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. (2015) (27)
Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer (1995) (27)
Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism (2007) (27)
The challenge of pancreatic cancer (2003) (26)
Randomized P hase I I C omparison o f D ose-Intense Gemcitabine: T hirty-Minute I nfusion a nd F ixed D ose R ate Infusion i n P atients W ith P ancreatic A denocarcinoma (2003) (26)
Glucose Metabolism Gene Variants Modulate the Risk of Pancreatic Cancer (2011) (26)
FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity. (2016) (26)
Novel therapies for pancreatic adenocarcinoma (2004) (26)
Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma (2012) (25)
Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). (2006) (25)
Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells (2013) (25)
Diagnostic protein discovery using proteolytic peptide targeting and identification. (2004) (24)
Knowledge of Indications and Utilization of EUS: A Survey of Oncologists in the United States (2008) (24)
Phase I and II studies of the combination of recombinant human interferon-γ and 5-fluorouracil in patients with advanced colorectal carcinoma (1989) (24)
A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer. (2006) (24)
Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography: A Comparison Study (2009) (24)
Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (1998) (24)
Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. (2010) (23)
The Bird's Nest Filter: An Alternative to Long‐Term Oral Anticoagulation in Patients with Advanced Malignancies (1994) (23)
Phase II study of gemcitabine in advanced colorectal adenocarcinoma (1992) (23)
Metastatic adenocarcinoma to the neck from an unknown primary source. (1991) (22)
Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. (1999) (22)
Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma (2014) (22)
Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation (2005) (22)
Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. (2001) (22)
The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer (2016) (22)
DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer (2012) (22)
Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt (2002) (22)
Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. (2005) (21)
A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. (1990) (21)
Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations (2013) (21)
Experimental animal models of pancreatic carcinogenesis and metastasis (2003) (21)
Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. (1995) (21)
Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. (1992) (21)
Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study (2003) (21)
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated (2006) (20)
Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. (1997) (20)
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. (1996) (20)
Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. (2013) (20)
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. (1996) (20)
The Nuclear Factor-kB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells (1998) (20)
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells (2009) (20)
Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. (2013) (20)
Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity (1989) (19)
Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. (2014) (19)
2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. (1993) (19)
A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma (2008) (19)
Phase I participants’ views of quality of life and trial participation burdens (2007) (19)
Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients (2006) (19)
Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: A case‐control study (2008) (19)
Genetic variants in the platelet‐derived growth factor subunit B gene associated with pancreatic cancer risk (2018) (19)
Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA) (2005) (19)
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204) (2017) (18)
Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies (1996) (18)
Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS (2019) (18)
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study (2006) (18)
Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. (1998) (17)
Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP) (2005) (17)
Curcumin and pancreatic cancer: Phase II clinical trial experience (2007) (17)
Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. (2015) (17)
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. (2011) (17)
Adjuvant therapy for surgically resected pancreatic adenocarcinoma. (2008) (17)
Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. (2019) (17)
Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. (2016) (17)
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. (2002) (17)
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. (2001) (17)
ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer (2015) (16)
Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). (2009) (16)
The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. (2013) (16)
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. (2008) (16)
Chemotherapy and radiation of anal canal cancer: the first approach. (2004) (16)
Single Nucleotide Polymorphisms of RecQ 1 , RAD 54 L and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer (2008) (16)
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer (2005) (16)
Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. (2007) (15)
Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. (2004) (15)
Carcinoma of Unknown Primary (2020) (15)
Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. (1995) (15)
A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. (2004) (15)
Hidden biases in an observational study of bevacizumab beyond progression. (2009) (15)
Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. (1984) (15)
Effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. (2011) (15)
Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells (2013) (14)
Randomized phase III Study of 5‐fluorouracil plus high dose folinic acid versus 5‐fluorouracil plus folinic acid plus methyl‐lomustine for patients with advanced colorectal cancer (1995) (14)
Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer. (2008) (14)
Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates. (2006) (14)
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. (1997) (14)
A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer (2005) (14)
Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin (2004) (13)
Genetic variants in the liver kinase B1‐AMP‐activated protein kinase pathway genes and pancreatic cancer risk (2019) (13)
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). (2018) (13)
Novel therapies for pancreatic adenocarcinoma (2004) (13)
New option for the initial management of metastatic pancreatic cancer? (2014) (13)
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma (1998) (13)
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. (1994) (13)
Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. (2006) (13)
Cytotoxic Chemotherapy for Pancreatic Cancer (2012) (13)
Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer (2008) (12)
Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC). (2006) (12)
Radiation Dose Considerations in the Palliative Treatment of Locally Advanced Adenocarcinoma of the Pancreas (2005) (12)
Artifactual frame-shift p53 mutation at codon 249 detected with the Cyclist DNA sequencing method. (1993) (12)
Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience (1995) (12)
Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. (1994) (12)
Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk (2019) (12)
Cell cycle regulation of human pancreatic cancer by tamoxifen (1998) (12)
A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma (2005) (12)
Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (2007) (12)
Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. (2009) (12)
Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections. (1983) (11)
A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. (1990) (11)
Phase II Trial of Gemcitabine Plus Irinotecan In Patients With Esophageal Cancer: A Southwest Oncology Group (SWOG) Trial (2006) (11)
Apoptotic and anti-vascular activity of imatinib in GIST patients (2005) (11)
WP1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo (2007) (11)
Phase II study of didemnin B in advanced colorectal cancer (1992) (11)
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. (2011) (11)
Genetic variants of the peroxisome proliferator‐activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer (2020) (11)
Expression of MAP 4 K 4 Is Associated withWorse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma (2008) (11)
NCCN practice guidelines for occult primary tumors (1998) (11)
In Vitro and in Vivo Antitumor Effect of the Anti-CD 26 Monoclonal Antibody 1 F 7 on Human CD 30 1 Anaplastic Large Cell T-Cell Lymphoma Karpas 2991 (2001) (10)
Intraperitoneal Fluid Neopterin, Nitrate, and Tryptophan After Regional Administration of Interleukin-12 (2003) (10)
Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer (2006) (10)
XRCC 2 and XRCC 3 Gene Polymorphism and Risk of Pancreatic Cancer (2008) (10)
Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. (2010) (10)
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis (2012) (10)
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. (1998) (10)
Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma (2008) (10)
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. (2003) (10)
Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. (1993) (10)
Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies (2012) (9)
Mouse models of metastatic pancreatic adenocarcinoma (2001) (9)
Chemoprevention of Pancreatic Cancer: Ready for the Clinic? (2010) (9)
Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. (2006) (9)
Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. (2008) (9)
Barriers to Integrating Gene Profiling for Stage II Colon Cancer (2009) (9)
A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. (2012) (9)
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. (1998) (8)
Cancer Metabolism and Its Therapeutic Implications (2013) (8)
Phase II study of amonafide in advanced pancreatic adenocarcinoma (1991) (8)
Phase-I and phase-ii trials of a laboratory-derived synergistic combination of Cisplatin and 2'-deoxy-5-azacytidine. (1995) (8)
Biochemical Modulation of 5-Fluorouacil Through Dihydropyrimidine Dehydrogenase Inhibition: a Southwest Oncology Group Phase II Trial of Eniluracil and 5-Fluorouracil in Advanced Resistant Colorectal Cancer (2002) (8)
Bad Blood: A Case Study of the Tuskegee Syphilis (1994) (8)
Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer. (2010) (8)
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study (2006) (8)
Molecular diagnosis of pancreatic and biliary cancer: ready for broad implementation? (2000) (8)
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer (2013) (7)
Phase II Study of MGI‐114 Administered Intravenously for 5 Days Every 28 Days to Patients With Metastatic Colorectal Cancer (2003) (7)
A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases (2007) (7)
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity (2021) (7)
Polymorphisms of phase II xenobiotic-metabolizing and DNA repair genes and in vitro N-ethyl-N-nitrosourea-induced O6-ethylguanine levels in human lymphocytes. (2007) (7)
Multi-institutional Phase II Trial of Induction Cetuximab Gemcitabine and Oxaliplatin, followed by R (2010) (7)
Stemming the tide of hepatitis B virus related hepatocellular carcinoma? (2008) (7)
Phase II trial of fazarabine in advanced colorectal carcinoma (1992) (6)
Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab (2004) (6)
Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? (2004) (6)
A phase II study of oxaliplatin and capecitabine (XELOX) in patients with unresectable cholangiocarcinoma, including carcinoma of the gallbladder and biliary tract (2005) (6)
Suppression of Tumorigenesis and Induction of p 15 ink 4 b by Smad 4 / DPC 4 in Human Pancreatic Cancer Cells 1 (2002) (6)
Abstract 1449: ApoStream™, a new dielectrophoretic device for antibody-independent isolation and recovery of circulating tumor cells from blood of patients with metastatic pancreatic adenocarcinoma. (2013) (6)
Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). (2012) (6)
Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique (1996) (6)
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. (2012) (5)
Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. (2012) (5)
S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5-Fluorouracil, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach (2009) (5)
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. (2016) (5)
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. (1989) (5)
Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma. (2002) (5)
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922) (2021) (5)
Phase I Study of 9‐Nitro‐20(S)‐Camptothecin in Combination with Cisplatin for Patients with Advanced Malignancies (2000) (5)
Chemoradiation for Localized Pancreatic Cancer: Another Perspective (1999) (5)
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. (2005) (5)
Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. (2012) (5)
Treatment related toxicities with rapid-fractionation external beam radiation therapy and concomitant gemcitabine for locally advanced nonmetastic adenocarcinoma of the pancreas (1998) (5)
Abstract B121: Phase I study of MK‐0646, a humanized monoclonal antibody against IGF‐1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced previously untreated pancreatic cancer (2009) (5)
A phase II study of capecitabine plus oxaliplatin and radiation therpy, XELOX-XRT, in squamous cell carcinoma (SCCA) of the anal canal: A preliminary analysis (2005) (5)
Antiangiogenic Cancer Therapy (2007) (5)
A phase I‐II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver (1993) (5)
Phase I studies of gemcitabine (1993) (5)
Serum CA 19–9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC) (2008) (4)
Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater (2008) (4)
Resected Pancreatic Cancer (2008) (4)
RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen (2004) (4)
Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. (2020) (4)
Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience (2021) (4)
Adjuvant therapy for pancreatic cancer: current status and future directions. (2004) (4)
Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma (1990) (4)
Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). (2010) (4)
Clinical Evaluation of Agents Targeting Epidermal Growth Factor Receptor (EGFR) in Cancer (2003) (3)
Novel approaches to 'borderline resectable' pancreatic tumors. (2008) (3)
Development and validation of a scoring system using insulin-like growth factor to assess hepatic reserve in hepatocellular carcinoma. (2014) (3)
135 Results of radiation and concomitant continuous infusion 5-fluorouracil and cis-platin for anal cancer (1997) (3)
Phase II Study of Intravenous CI-958 in Metastatic Colorectal Adenocarcinoma (2000) (3)
Abstract C26: Development and validation of a scoring system using insulin-like growth factor to assess hepatic reserve in hepatocellular carcinoma. (2013) (3)
A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity. (2018) (3)
Treatment of localized, potentially resectable disease (2003) (3)
Erratum: Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome (PLoS ONE (2013) 8:7 DOI: 10.1371/annotation/6afdd046- e1a7-4421-b7ec-0c9492ce2544) (2013) (3)
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer (2004) (3)
Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC) (2004) (3)
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study (2004) (3)
Background and H2O2-induced micronuclei in peripheral blood lymphocytes as a risk factor for pancreatic cancer (2004) (3)
Use of gene expression analysis of periampullary carcinomas to identify biliary-like and intestinal-like subgroups of ampullary and duodenal carcinomas. (2011) (3)
Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas (1991) (3)
5-FU-based adjuvant chemotherapy given after neoadjuvant chemoradiation and surgery for rectal cancer improves survival only among responders (2001) (3)
Patients with carcinoma of unknown primary and “colon cancer profile”: Clinicopathologic features and survival data. (2012) (3)
Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. (1999) (3)
Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study (2016) (3)
Abstract 898: Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer (2010) (3)
Asn and Lys 751 Gln polymorphisms , corresponding haplotype , and pancreatic cancer risk (2008) (3)
Reassessing Hepatocellular Carcinoma Staging in a Changing Patient Population (2014) (3)
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer (2008) (3)
High expression level of insulin-like growth factor I receptor is associated with regional lymph node metastasis. (2004) (3)
Loss of PTEN Expression Is Associated with Recurrence and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma (2013) (3)
Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. (2018) (2)
Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents (1998) (2)
Pancreatic Cancer Cells Kinase and Induces Apoptosis via ER Stress in Human Bortezomib Inhibits PKR-Like Endoplasmic Reticulum ( ER ) (2005) (2)
HLA-A0201 positive pancreatic cell lines: new findings and discrepancies (2007) (2)
A phase I trial of TAS-102 administered on a three times a day schedule in patients with solid tumors. (2006) (2)
Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC). (2004) (2)
Pancreatic ductal adenocarcinoma: neoadjuvant therapies and pathology (2014) (2)
Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma (1993) (2)
Treatment of Pancreatic Cancer (2005) (2)
Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer. (2003) (2)
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer. (1989) (2)
REVISION CARCIN-2008-00096 Interaction of the Cytochrome P4501A2, SULT1A1 and NAT Gene Polymorphisms with Smoking and Dietary Mutagen Intake in Modification of the Risk of Pancreatic Cancer (2007) (2)
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors. (2021) (2)
The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC). (2009) (2)
Precancerous lesions of the digestive tract: The 18th Annual Symposium of the European Cancer Prevention Organisation Maastricht, The Netherlands, 12-14 October 2000 (2000) (2)
Preoperative chemoradiotherapy, pancreaticoduodenectomy, and external- beam intraoperative radiotherapy for pancreatic adenocarcinoma: The M.D. Anderson experience (1994) (2)
149 INVITED Are there rational novel targets for pancreatic cancer therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in Pancreatic Cancer (2007) (2)
Comparison of ampullary adenocarcinomas and duodenal adenocarcinomas with regard to clinical outcomes and responsiveness to fluoropyrimidine-based chemotherapy. (2011) (2)
P66: An integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer (2007) (2)
Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer (2008) (2)
Molecular genetics of pancreatic cancer (1998) (2)
Nuclear factor-K B maintains TRAIL resistance in human pancreatic cancer cells (2006) (2)
1002 TGF-β-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance (2009) (2)
Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis (2021) (2)
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. (2022) (2)
Use of DPC-4 immunostaining of diagnostic cytology specimens to predict the pattern of tumor progression in locally advanced pancreatic cancer patients (LAPC). (2011) (2)
Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma (2022) (2)
Presumed malignant biliary obstruction despite a normal CT: Data to support pancreatico-duodentectomy (PD) (1998) (2)
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma (1991) (2)
Emerging Therapeutic Targets in Pancreatic Adenocarcinoma (2016) (2)
Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma (1988) (2)
Association of manganese superoxide dismutase polymorphism and smoking to pancreatic cancer (2005) (2)
Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs (2007) (2)
Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. (2004) (2)
Are time or intensity factors important to the definition of metastases of unknown origin? (1996) (2)
Epidermal Growth Factor Receptor Blockade with C 225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms 1 (2000) (2)
Who should go first in trials with scarce agents? The views of potential participants. (2007) (1)
The treatment of colorectal carcinoma: standard chemotherapy and beyond. (2004) (1)
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma (1)
IV-HCC: Clinical and prognostic implications of plasma IGF-1 and VEGF in patients with hepatocellular carcinoma. (2011) (1)
Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations (2013) (1)
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study (2004) (1)
Phase Ii trial of 5-fluorouracil, folinic acid and recombinant α-2a-interferon in patients with advanced colorectal cancer (1999) (1)
The novel poly(ADP-ribose) polymerase (PARP) -1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer (2007) (1)
Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC). (2012) (1)
Transforming growth factor (TGF) beta pathway and clinical outcome of pancreatic cancer. (2012) (1)
Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. (2010) (1)
Gemcitabine and cisplatin chemotherapy for patients with metastatic esophageal carcinoma (2001) (1)
Joint United States of America (USA)/Japan study of UFT (uracil and tegafur) plus leucovorin (LV) in patients (pts) with metastatic colorectal cancer (CRC) (2001) (1)
Phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine (GEMOX) in cancer of unknown primary (CUP) (2005) (1)
Adenocarcinoma of the pancreas (1996) (1)
Pancreatic injury, genetic variation of PNPLA3, and risk of pancreatic cancer. (2013) (1)
Abstract 2760: Phase I study of MK-0646, the humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced, previously untreated pancreatic cancer (2010) (1)
Abstract 891: FGF21 prevents high fat diet-induced pancreatic cancer in mice expressing oncogenic Kras (2015) (1)
Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial (2021) (1)
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid (2008) (1)
Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC). (2011) (1)
Gemcitabine resistance in cultured pancreatic tumor cells is associated with down regulation of PTEN and a mesenchymal phenotype (2008) (1)
Strategies for Chemoprevention in Pancreatic Cancer (2005) (1)
Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. (2010) (1)
Correlation of single nucleotide polymorphisms (SNPs) of hypoxia-related genes with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer. (2010) (1)
15 – Patterns of Metastasis during Progression of Colorectal Cancer in Humans (1990) (1)
Introducing CCR Practice of Translational Oncology (2006) (1)
The association between statin use and hepatocellular cancer outcome. (2013) (1)
Mouse models of metastatic pancreatic adenocarcinoma. (2001) (1)
Randomized Controlled Trial Resection of Pancreatic Adenocarcinoma: A After Fluorouracil-Based Chemoradiation Following Fluorouracil vs Gemcitabine Chemotherapy Before and (2009) (1)
Correction: Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome (2013) (1)
A pilot-study of Paclitaxel in previously treated patients with metastatic unknown primary carcinomas. (1995) (1)
O-0004 Updated Analysis of Phase II Study of the Anti-IGF-1R Antibody MK-0646 with Gemcitabine +/- Erlotinib for Advanced Pancreatic Cancer (APC) (2012) (1)
Adenocarcinoma of the liver without a detectable primary. (1991) (1)
328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer (2008) (0)
Abstract #LB-148: Mast cells in the tumor microenvironment are essential for the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) (2009) (0)
XELOX Safe, Effective as First-Line Therapy for Metastatic Colorectal Cancer (2004) (0)
T1524: Clear Bile on ERCP for Malignant Biliary Obstruction - Incidental Finding or an Ominous Sign? A Comparative Study (2010) (0)
Phase II study of Adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma (1989) (0)
Phase II Trial of Isotretinoin and Recombinant Interferon Alfa‐2a in Metastatic Colorectal Carcinoma (1995) (0)
'Unresectable' pancreatic cancer: Conceptual challenges (2007) (0)
Perioperative chemotherapy improved survival in resectable adenocarcinoma of the stomach or lower esophagus. (2007) (0)
536 Oncogenic Ki-RAS-miR-21 Signaling Promotes AKT Activation in Pancreatic Cancer Cells Through a Novel AKT-Interacting Protein Bsta (2013) (0)
Statins Cut Colon Ca Risk, Retrospective Study Shows; Further Investigation Warranted (2005) (0)
Highlights of the 2008 San Antonio Breast Cancer Symposium. (2009) (0)
Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer (2018) (0)
Comprar Antiangiogenic Cancer Therapy | James L. Abbruzzese | 9780849327995 | Informa Healthcare (2007) (0)
Familial tendency of hepatocellular carcinoma in USA (2008) (0)
Advances in Therapy for GI Cancers (2005) (0)
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer (2005) (0)
Markers May Help Select Patients for Adjuvant Therapy (2004) (0)
Translational clinical trial design (2008) (0)
Evaluating physician performance in oncology: moneyball becomes impactball. (2014) (0)
Capecitabine Improved Safety Profile Maintained in Older Pts With Colon Ca (2004) (0)
Celecoxib Plus Chemotherapy Promising in Advanced Pancreatic Cancer (2004) (0)
Hepatitis C as a predictor of treatment outcome in patients with hepatocellular carcinoma treated with the retinoid derivative, TAC-101. (2011) (0)
[Frontiers in Bioscience 3, e194-204, November 1, 1998] 194 NEOADJUVANT CHEMORADIATION FOR ADENOCARCINOMA OF THE PANCREAS (1998) (0)
New Combinations, Increased Use of Markers Predicted in GI Cancers (2004) (0)
Avastin Enhances FOLFOX Efficacy (2005) (0)
Abstract 616: R1507, the human monoclonal antibody targeting the insulin-like growth factor receptor (IGF-1R), in combination with cetuximab, can reverse acquired resistance to cetuximab in pancreatic and colon cancer models (2010) (0)
Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment (1999) (0)
Editorial review: Unknown primary tumors (1992) (0)
CHFR methylation as an epigenetic marker for recurrence of colon cancer. (2009) (0)
Abstracts reprinted from Journal of Clinical Oncology (2007) (0)
LINICAL — ALIMENTARY TRACT ntidiabetic Therapies Affect Risk of Pancreatic Cancer (0)
Treatment of locally advanced disease (2003) (0)
A NOVEL NON-TOXIC MULTI-TARGETED APPROACH FOR PANCREATIC CANCER THERAPY (2007) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
980 Preliminary results of a phase I study of rhumab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) in locally advanced pancreatic cancer (2003) (0)
bcl-2 and p 53 Expression in Resectable Pancreatic Adenocarcinomas : Association with Clinical Outcome 1 (2005) (0)
NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM). (2018) (0)
Endoscopic management of biliary tract cancer with the wallstent: Experience in 121 patients (1997) (0)
United States Patent ( 19 ) Chu 54 HYDROCARBON RESISTANT SEALANT (2017) (0)
Adding Bevacizumab Improves Response to Oxaliplatin Regimens (2005) (0)
Recently Released Data Show Benefits of FOLFOX4 Extend to Adjuvant Setting (2004) (0)
Advancing Treatment of GI Cancers (2004) (0)
A phase I clinical trial of recombinant human endostatin in patients with solid tumors Surrogate analyses to determine a biologically effective dose (2001) (0)
Induction Ofp 2 Jwaf . l Expression and Growth Inhibition by Transforming Growth Factor 1 @ Involve the Tumor Suppressor Gene DPC 4 in Human Pancreatic Adenocarcinoma Cells (2006) (0)
Single-Nucleotide Polymorphisms of DNADamage Response Genes AreAssociated with Overall Survival in Patients with Pancreatic Cancer (2008) (0)
Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study. (2023) (0)
Abstract 4672: Overexpression of NR5A2/LRH1 in pancreatic cancer and possible association with clinical outcome (2011) (0)
Pancreatic, Hepatic, and Biliary Carcinoma (2005) (0)
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance (2010) (0)
Introducing CCR Perspectives in Drug Approval (2011) (0)
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) (2009) (0)
Abstract B101: Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer. (2013) (0)
A CANCER VACCINE TARGETING NOTCH: IMPLICATIONS FOR IMMUNOTHERAPY AGAINST PANCREATIC CANCER STEM CELLS (2008) (0)
Introduction (0)
Abstract 4437: Fbxw8 targets hematopoietic progenitor kinase 1 for proteasomal degradation (2014) (0)
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial (2023) (0)
Pharmacodynamic evaluation of plasma thioredoxin-1 for patient enrichment of PX-12 clinical trials. (2008) (0)
Pancreatic Adenocarcinoma-mediated Suppression of Growth and Metastasis of β Gene Is Required for Interferon-Nitric Oxide Synthase II Intact Updated Version (2000) (0)
Cisplatin, 5-Fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. (1995) (0)
Introducing New Strategies in... (2010) (0)
PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER (2008) (0)
SyntheticMicroRNADesignedtoTargetGlioma-AssociatedAntigen1 TranscriptionFactor InhibitsDivisionand InducesLate Apoptosis inPancreaticTumorCells (2006) (0)
EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors (2022) (0)
Chapter 35 – Molecular Pathogenesis of Pancreatic Adenocarcinoma (2008) (0)
Molecular Therapeutics: Pancreatic Cancer (2015) (0)
Phase I I a nd P harmacodynamic S tudy o f t he Farnesyltransfer ase I nhibitor R 115777 a s I nitial T herapy i n Patients W ith M etastatic P ancreatic A denocarcinoma (2003) (0)
556 POSTER Novel small molecule inhibitors of Jak2/STAT3 pathway: design, structurte-activity relationship, and oral bioavilability (2006) (0)
Synergistic cytotoxicity as an endpoint for the development of rational chemotherapeutic. Drug combinations (1994) (0)
1040 Development of a bowel function assessment tool to measure bowel function in patients receiving radiation and/or chemotherapy (1997) (0)
Correction: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines (Cancer Research (2006) 66, 7, (3802-3812)) (2010) (0)
Eloxatin Approved for First‐Line Treatment of Metastatic Colorectal Cancer (2004) (0)
Alcohol, Obesity, and Smoking Risk Factors for HCC (2005) (0)
Early Results Promising for Autologous HSP Vaccine in Pancreatic Cancer (2004) (0)
Pancreatic Cancer Cell Lines Activation and Sensitivity to Gefitinib ( Iressa ) in Human Constitutive Epidermal Growth Factor Receptor Pathway Expression Drives α Transforming Growth Factor Updated (2006) (0)
A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. (2001) (0)
Chemoradiation With Capecitabine Comparable to 5-FU in Locally Advanced Rectal Cancer (2004) (0)
Study of genotypic variations and protein expression of the xCT subunit of cystine/glutamate transporter in pancreatic cancer. (2011) (0)
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) (2007) (0)
Erlotinib/Gemcitabine Ups Survival in Advanced Pancreatic Cancer (2003) (0)
Clinical Cancer esearch New Strategies Strategies in Pancreatic Cancer : Emerging R emiologic and Therapeutic Concepts (2010) (0)
Novel Approaches to ‘ Borderline Resectable ’ Pancreatic Tumors November (2017) (0)
Reply to A. Goyal et al (2012) (0)
Phase I S tudy o f P reoperative O ral U racil a nd T egafur Plus L eucovorin a nd R adiation T herapy i n R ectal C ancer (2000) (0)
82. Targeted Pancreatic Cancer-Specific Gene Therapy Controlled by a Molecular-Engineered Human Cholecystokinin Type-A Receptor (CCKAR) Promoter in In Vivo Imaging Models (2005) (0)
Abstract 4560: A new IGF-1-integrated Child-Pugh score to risk-stratify patients with hepatocellular carcinoma (2012) (0)
Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). (2010) (0)
Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT (2011) (0)
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer (2019) (0)
Adjuvant Chemotherapy Should Follow Pancreaticoduodenectomy for Pancreatic Adenocarcinoma, Despite Delays (2018) (0)
Growth Inhibitory Effects of Sodium Phenylacetate ( NSC 3039 ) on Ovarian Carcinoma Cells in Vitro 1 (2006) (0)
The effect of anti-IGF1 therapy on muscle mass in metastatic pancreatic cancer. (2013) (0)
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. (2023) (0)
1602 Pathologic Complete Response Is Associated with Good Prognosis in Patient with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Chemoradiation and Pancreatectomy. (2011) (0)
Pancreatic cancer targeted C-VISA-BikDD: DNA-liposome complex results in minimal toxicity in vivo. (2007) (0)
Panitumumab, Anti-EGFR MoAb,Promising in Colon Cancer (2005) (0)
778 Morbidity and Mortality After Pancreaticoduodenectomy in Patients With Borderline Resectable Type C Clinical Classification (2013) (0)
CCR Translations Barriers to Integrating Gene Profiling for Stage II Colon Cancer (2009) (0)
Pancreatic and hepatobiliary cancer (2003) (0)
Phase I study to determine the safety and pharmacokinetics of 4-hour intravenous infusion of TAS-106 on a once per week for 3 consecutive weeks every 28-day schedule in patients with solid tumors (2007) (0)
Imaging, Diagnosis, Prognosis Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer (2011) (0)
Abstract 5527: Overexpression of protein phosphatase 4 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma (2012) (0)
Aspirin Raised Pancreatic Ca Risk in Large Nurses’ Study (2004) (0)
131 Pharmacodynamic analysis of apoptosis and anti-vascular activity in GIST patients treated with Imatinib (2004) (0)
Comprar Pancreatic Cancer | Neoptolemos, John P. | 9780387774985 | Springer (2010) (0)
Comparison between metastatic vs primary biliary tract cancer in their response to the Wallstent (1997) (0)
ABSTRACTS Session 2: Pancreatic Cancer Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. (2012) (0)
THE EVOLVING INFLAMMATORY STATUS IN A TRANSGENETIC SPONTANOUS PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) MOUSE MODEL (2008) (0)
Roles of endocrine FGF signaling in metabolic health and cancer (2014) (0)
Abstract 1493: Analysis of fibrosis and stromal components in metastatic pancreatic cancer (PC) autopsy specimens (2012) (0)
Gene profiling validation for cancer classification using known primary carcinoma samples (2007) (0)
Intraoperative RT Useful in Unresectable Pancreatic Cancer (2004) (0)
Capecitabine/Irinotecan Combination Regimens Active as First-Line Treatment of Metastatic Colorectal Cancer (2004) (0)
A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. (2021) (0)
34 POSTER A phase II study of the combination of bevacizumab and erlotinib in patients with patients with unresectable hepatocellular carcinoma (2006) (0)
Abstract #2759: Thymoquinone-induced E2F-1 downregulation and induction of apoptosis enhances gemcitabine effects in pancreatic cancer (2009) (0)
Study Strengthens Evidence of Link Between Liver Cancer and Diabetes (2005) (0)
Plans for ISGIO's Fourth Annual GI Oncology Conference Under Way (2007) (0)
High expression level of insulin-like growth factor I receptor is associated with regional lymph node metastasis (2004) (0)
Knowledge of Indications and Utilization of EUS: Survey of Oncologists in the USA (2006) (0)
Contents Vol. 80, 2011 (2011) (0)
Staging of advanced hepatocellular carcinoma patients in the targeted therapy era. (2012) (0)
Association of RecQ1 A159C polymorphism with overall survival of patients with resected pancreatic cancer: A replication study in RTOG 9704. (2011) (0)
615 POSTER Nuclear coactivator/corepressor expression ratio predicts survival in hepatocellular carcinoma patients treated with TAC-101, a synthetic retinoid (2006) (0)
Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS (2019) (0)
Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. (2014) (0)
218 A Randomized Phase II Study of Gemcitabine 1000mg/msq and Concurrent Radiotherapy Comparing Gemcitabine Alone for Unresectable Locally Advanced Pancreatic Adenocarcinoma (2010) (0)
Development and validation of an IGF-1-modified Child-Pugh score to risk-stratify hepatocellular carcinoma patients (2015) (0)
Reply: (2009) (0)
Serum Amyloid A (SAA) in Patients with Pancreatic Carcinoma (2004) (0)
Systematic survey of therapeutic trials for metastatic colorectal cancer. (2012) (0)
Polymorphisms of RecQ1, RAD54L, ATM and XRCC1 genes and prognosis of pancreatic cancer (2006) (0)
Conservative management of anal and low rectal cancers with combined modality therapy (1989) (0)
Abstract 4491: Transforming growth factor (TGF) ≤ pathway and clinical outcome of pancreatic cancer (2012) (0)
Treatment of metastatic disease (2003) (0)
Prospective study of a 10-gene molecular assay to predict tissue of origin in patients with carcinoma of unknown primary (CUP) (2016) (0)
2004 Sees FDA Approval of Two Tumor Growth Inhibitors for Colorectal Cancer (2004) (0)
Phase II trial of intravenous melphalan in advanced colorectal carcinoma (2004) (0)
Chemoradiotherapy Before Surgery Improves Outcomes in Patients With Rectal Cancer (2004) (0)
Principles of Gene Therapy as Related to Practice of Interventional Radiology (2000) (0)
Serum Amyloid A (SAA) in Patients with Pancreatic Carcinoma. (2004) (0)
Letter from the editor (2001) (0)
Molecular Pathogenesis of Pancreatic Adenocarcinoma (2014) (0)
Abstract 3655: Mast cells promote immunosuppression and pancreatic ductal adenocarcinoma development (2011) (0)
A phase-I clinical-trial of a protracted continuous-infusion of 5-Fluorouracil with oral folinic Acid in patients with unresectable adenocarcinoma of the colon or rectum. (1995) (0)
JAMA Peer Reviewers in 2018. (2019) (0)
Abstract 3750: Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer (2011) (0)
Assessing the Ethics of Ethics Research: A Case Study (2004) (0)
Cetuximab (C225) Plus Cisplatin (CDDP) Irinotecan (CPT11) and Thoracic Radiotherapy (TRT) Definitive Treatment for Locally-advanced, Clinically Unresectable Esophageal Cancer: A Southwest Oncology Group (SWOG) Phase II Trial with Molecular Correlates (S0414) (2009) (0)
Function of Nuclear Factor (cid:1) B in Pancreatic Cancer Metastasis 1 (2003) (0)
Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies. (2015) (0)
Conservation management of rectal cancer at m. d. anderson cancer center 1978 – 1988: Techniques, treatment results and assessment of gastrointestinal and sexual function (1989) (0)
CHAPTER 22: CARCINOMA OF UNKNOWN PRIMARY (2001) (0)
54 Emerging Therapeutic Targets for Pancreatic Cancer (2010) (0)
HER-2-Nascent Polypeptide Chain Bound on Ribosomes Translating Influenza Virus Proteins Induces Differentiation of CD8+ Cells (2005) (0)
Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors (2002) (0)
cDNA-based comparative genomic hybridization (cCGH) analysis of genomic aberrations of pancreatic cancer cells. (2004) (0)
Original article Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors (2005) (0)
Important Advances in Treatment of Colorectal Cancer Presented at ASCO 2003 (2004) (0)
Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer (2019) (0)

This paper list is powered by the following services:

Other Resources About James Lewis Abbruzzese

en.wikipedia.org

What Schools Are Affiliated With James Lewis Abbruzzese?

James Lewis Abbruzzese is affiliated with the following schools:

James Lewis Abbruzzese's Academic­Influence.com Rankings

James Lewis Abbruzzese's Degrees

Why Is James Lewis Abbruzzese Influential?

James Lewis Abbruzzese's Published Works

Published Works

Other Resources About James Lewis Abbruzzese

What Schools Are Affiliated With James Lewis Abbruzzese?

James Lewis Abbruzzese's AcademicInfluence.com Rankings